David L. Barker, PhD
Chairman

Dr. David L. Barker currently serves on the Boards of Directors of AmideBio and Singular Genomics Systems, and is Board Member and Chairman at Integrated Diagnostics and BioNano Genomics.

Read More

He is a scientific advisor to MiNDERA Corp. and Luna DNA. He was Vice President and Chief Scientific Officer at Illumina, Inc., from 2000 to 2007, and on the Illumina scientific advisory board through 2015. He was previously on the Boards of NextBio, which was acquired by Illumina in 2013, ProteinSimple, which was acquired by Bio-Techne in 2014, Zephyrus Biosciences, Inc., which was acquired by Bio-Techne in 2016, and IntegenX, which was acquired by Thermo Fisher Scientific in 2018.
Dr. Barker is a board member of the non-profit foundation Summit for Stem Cell, which supports research toward an autologous dopamine neuron replacement therapy for Parkinson’s disease.
Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham.
In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.

Read Less
Erik Holmlin, PhD
PRESIDENT AND CHIEF EXECUTIVE OFFICER

Erik Holmlin is a dynamic leader with more than two decades of experience developing innovative solutions and companies in the life sciences and healthcare industries.

Read More

Erik’s experience includes positions at GenVault Corporation (CEO), Exiqon A/S (CCO) and Becton Dickinson (vice president of marketing and development). In 2001, Erik led the formation and financing efforts of GeneOhm Sciences, Inc. and orchestrated the company’s acquisition by Becton Dickinson in 2006. He also served as an entrepreneur in residence (EIR) at leading life-science venture capital firm Domain Associates, LLC.

Erik was a National Institutes of Health postdoctoral fellow at Harvard University and a National Science Foundation predoctoral fellow at the California Institute of Technology, Pasadena (Caltech). He holds a PhD in chemistry from Caltech and MBAs from UC Berkeley and Columbia University.

Read Less
Darren Cai, PhD
Director

Dr. Cai has served on our board of directors since September 2014.

Read More

From April 2015 to April 2018, Dr. Cai served as a Managing Director of Legend Capital, a Chinese early stage and expansion stage venture capital firm, and held a previous position as a Director of Legend Capital from October 2012. Dr. Cai also served as Chief Financial Officer of Beijing Genomics Institute, a genome sequencing company, from 2014 to 2016. During his tenure at Legend Capital, Dr. Cai focused on investment opportunities in the healthcare sector and led investment in more than 20 companies located in the U.S. and China. In addition, Dr. Cai previously served on the board of directors of Beijing Genomics Institute. Dr. Cai received his bachelor’s degree in biophysics from the University of Science and Technology of China, MBA from Yale University and Ph.D. in vision science from the University of California, Berkeley. Our board of directors believes Dr. Cai’s extensive experience in managing and developing investment and business opportunities within the health care sector qualifies him to serve on our board of directors.

Read Less
Junfeng Wang
Director

Mr. Junfeng Wang has served on our board of directors since February 2018.

Read More

Since October 2009, Mr. Wang has served as a Managing Director of Legend Capital, and held previous positions with Legend Capital as Executive Director from October 2007, Senior Vice President from October 2006 and Vice President from October 2005. Through his tenure at Legend Capital, Mr. Wang has worked in the healthcare and chemical industries, developing research and investment expertise in growth capital investment. Mr. Wang received his bachelor’s degree in polymer chemistry from Lanzhou University, a research university located in China, and his MBA from McMaster University, a research university located in Canada. Our board of directors believes Mr. Wang’s extensive experience as a venture capital investor in the healthcare and chemical industries qualifies him to serve on our board of directors.

Read Less
Albert Luderer, PhD
Director

Albert Luderer has three decades of experience in biotechnology, with special focuses on technology, business development and commercialization.

Read More

Dr. Luderer is CEO and board director at personalized diagnostics company Integrated Diagnostics. He also serves as CEO and board director of molecular therapeutics and imaging company Indi Molecular.

Dr. Luderer previously served as president and CEO of BioTrove, a venture-backed molecular biological tools company that was acquired by Life Technologies. Additionally, Dr. Luderer was CEO of venture-backed therapeutics company Light Sciences and president and COO of bioMérieux, Inc.

Senior management positions at Dianon Systems (LabCorp), Boehringer Mannheim (Roche), and Corning round out Dr. Luderer’s experience in the industry. He earned his PhD from Rutgers University, where he was a National Science Foundation predoctoral fellow, and performed postgraduate work in immunology at Jefferson Medical College.

Read Less
Quan Zhou
Director

Mr. Zhou has served on our board of directors since February 2018.

Read More

Since April 2016, Mr. Zhou has served as an Executive Director at Legend Capital, and held previous positions as Director from April 2015 and Vice President from October 2012. During his tenure at Legend Capital, Mr. Zhou has focused on the Medtech and diagnostics industries. Mr. Zhou received his bachelor’s degree in Biology from the University of Science and Technology in China, his Masters in Neuroscience from the National University of Singapore, and his MBA from the China Europe International Business School. Our board of directors believes Mr. Zhou’s extensive experience in investment in the healthcare sector qualifies him to serve on our board of directors.

Read Less
Christopher Twomey
Director

Christopher J. Twomey has served on our board of directors since July 2018.

Read More

Since August 2013, Mr. Twomey has served as a director and Chairman of the Audit Committee of Tandem Diabetes Care, Inc., a medical device company. Since March 2006, Mr. Twomey has served as a director and Chairman of the Audit Committee of Senomyx, Inc., a taste technologies company. From March 1990 to June 2007, Mr. Twomey served in various roles of increasing responsibility, including as Senior Vice President, Finance and Chief Financial Officer, at Biosite Incorporated, a medical diagnostics company, until it was acquired by Inverness Medical in 2007. While serving at Biosite, Mr. Twomey was responsible for the Finance, Human Resources, Facilities, and Information Systems departments. From October 1981 to March 1990, Mr. Twomey served as an audit manager for Ernst & Young, LLP. Mr. Twomey also served as a director and Chairman of the Audit Committee of Cadence Pharmaceuticals, Inc., a specialty pharmaceutical company that was acquired by Mallinckrodt plc in 2014. Mr. Twomey received his B.A. in Business Economics from the University of California at Santa Barbara.

Read Less
Top